Download Current Trials Open to Accrual Breast Cancer As of 10/8/2014

Current Trials Open to Accrual
Breast Cancer
As of 10/8/2014
REGISTRY/SYMPTOM MANAGEMENT
AMG 20101102: Osteonecrosis of the Jaw Registry (UIC IRB# 2012-1024)
DCIS/EARLY STAGE
CALGB 40903 - Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women with Estrogen Receptor Positive Ductal
Carcinoma In Situ (DCIS) (UIC IRB# 2012-0917)
NSABP B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy
Alone for Women with HER2- Positive Ductal Carcinoma In Situ Resected by Lumpectomy (UIC IRB# 2012-0534)
SWOG S1202: A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor (AI)-Associated
Musculoskeletal Symptoms in Women with Early Stage Breast Cancer
MULTIPLE IPSILATERAL BREAST CANCERS
ACOSOG Z11102: Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral
Breast Cancers (MIBC)
ER+/PR+/HER2+ and/or LOCALLY-ADVANCED
NSABP B-52: A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone ReceptorPositive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel,
Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation (UIC IRB# 2014-0184)
AbbVie M12-914: Phase III Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel with or without the PARP Inhibitor
Veliparib (ABT-888) in Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer (UIC IRB# 2014-0718)
ER+/PR+/HER2SWOG S1007: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3
Positive Nodes, Hormone Receptor- Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less (UIC IRB#
2011-0684)
NODE + or HIGH-RISK NODE - / HER2 +
NSABP B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of TC or Four Cycles of
AC Followed by Four Cycles of Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk
Node-Negative HER2-Normal Invasive Breast Cancer (UIC IRB# 2011-0737)
HIGH-RISK HORMONE RECEPTOR + / HER/NEU –
SWOG S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One
Year of Everolimus in Patients with High-Risk Hormone Receptor-Positive and HER/NEU Negative Breast Cancer (UIC IRB# 20130232)
ADVANCED/METASTATIC
ECOG E2108: A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with
Metastatic Breast Cancer (UIC IRB# 2011-1010)
AbbVie M12-895: A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination with Temozolomide or
Veliparib in Combination with Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin in Subjects with BRCA1 or BRCA2 Mutation
and Metastatic Breast Cancer (UIC IRB# 2013-0711)
MONALEESA LEE011: A Randomized Double-Blind, Placebo- Controlled Study of LEE011 in Combination with Letrozole for the
Treatment of Postmenopausal Women with Hormone Receptor Positive, HER3 negative Advanced Breast Cancer Who Received No
Prior Therapy for Advanced Disease (UIC IRB# 2013-1123)
PHASE I SOLID TUMOR STUDIES
STM-01: Phase I Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) Given in Combination with Selective VEGFR Inhibitor
Pazopanib (Votrient) for Therapy of Solid Tumors (UIC IRB# 2013-0100)
STM-02: Phase I Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Solid Tumors Expressing IGFR (UIC IRB#
2013-0655)
For screening potential patients, please call:
JEN ELVIKIS, RN, MSN
Phone: 5-5767
In-House Pager: 136-5548
Email: [email protected]